Dosage Information for Kadcyla: Its form, potencies, administration methods, and additional facts
Kadcyla, a drug used to treat HER2-positive breast cancer, comes in two strengths: 100 milligrams (mg) and 160 mg. Regardless of the stage of the breast cancer — early or metastatic — the dosage and administration of Kadcyla remain the same.
The typical dosing regimen for Kadcyla is 3.6 mg/kg administered intravenously every 3 weeks, forming a 21-day cycle. This regimen continues until disease progression or unacceptable toxicity occurs. In the case of metastatic HER2-positive breast cancer, Kadcyla may be used as a single agent or in combination with other HER2-targeted therapies like tucatinib.
This established standard is based on clinical trials and approved prescribing information for Kadcyla in HER2-positive breast cancer.
It's important to note that Kadcyla has boxed warnings about the risks of severe heart and liver problems. Individual dosages may vary based on the prescription of a doctor, and other medical conditions can also affect the Kadcyla dosage.
Kadcyla belongs to the drug class called antibody-drug conjugates. If a patient misses a Kadcyla infusion appointment, they should contact their doctor's office immediately.
Kadcyla is not available in a biosimilar version. It is prescribed as an adjuvant therapy for early breast cancer and can be used as a long-term treatment for certain types of HER2-positive breast cancer in adults.
The first infusion typically takes 90 minutes, while future infusions may last 30 minutes if no infusion-related reactions occur. Kadcyla comes as a solution for intravenous (IV) infusion, mixed with sterile water.
If a patient develops certain side effects, the doctor may adjust the dosage, pause, or stop treatment. Kadcyla is a biologic drug, meaning it is made from living organisms.
The recommended dose of Kadcyla for early breast cancer is an IV infusion of 3.6 mg/kg of body weight, usually once every 3 weeks for a total of 14 cycles. For metastatic breast cancer, the recommended dose is also 3.6 mg/kg of body weight, given once every 3 weeks, continued as long as the drug is safe and effective.
The dosage prescribed depends on factors such as the stage of breast cancer, body weight, and presence of serious side effects. The length of treatment depends on the type of breast cancer, side effects, and whether the cancer returns.
- The drug Kadcyla, used for treating breastcancer, is a biologic medication that comes in two strengths: 100 mg and 160 mg.
- In oncology, Kadcyla is typically dosed at 3.6 mg/kg intravenously every 3 weeks, creating a 21-day cycle, depending on factors such as the stage of breast cancer or the presence of medical-conditions.
- Kadcyla belongs to the drug class called antibody-drug conjugates and is prescribed for both early and metastatic breast cancer, sometimes even as a long-term treatment for certain types of HER2-positive breast cancer in adults.
- If a patient misses a scheduled Kadcyla infusion, they should immediately contact their doctor's office, and it's important to note that Kadcyla has boxed warnings about the risks of severe heart and liver problems.
- Individual dosages may vary based on the prescription of a doctor, the type and severity of a patient's health-and-wellness condition, and the progression of their breastcancere.
